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Host eicosanoids are lipid mediators of inflammation that are commonly accepted as
important modulators of the host immune response in Mycobacterium tuberculosis
infection. During active tuberculosis (TB), eicosanoids may play an important role in
the regulation of inflammatory responses. However, a detailed investigation of the
relationship of eicosanoids in TB and TB-diabetes comorbidity (TB-DM) and association
to disease pathology or bacterial burdens has not been studied. To study this, we
examined the plasma levels of Lipoxin A4 (LXA4), 15-epi-LXA4, Leukotriene B4 (LTB4),
and Prostaglandin E2 (PGE2) in individuals with either TB-DM, TB, diabetes mellitus
(DM) or healthy controls (HC). Plasma levels of LXA4, 15-epi-LXA4, and PGE2 were
significantly increased while the levels of LTB4 were significantly decreased in TB-DM
and TB group compared to DM and HC. The ratio of LXA4 to LTB4 and 15-epiLXA4
to LTB4 was significantly enhanced in TB-DM compared to TB. Moreover, the levels
of LXA4, 15-epi-LXA4 and the ratios of LXA4 to LTB4 and 15-epiLX4 to LTB4 were
significantly increased in TB individuals with bilateral or cavitary disease and these
markers also revealed a significant positive relationship with bacterial burden. At the
completion of anti-tuberculosis therapy (ATT), levels of LXA4, 15-epi-LXA4, and PGE2
in TB-DM and TB groups were diminished and levels of LTB4 were enhanced in the
TB group compared to pre-treatment. Our data imply that alteration and upregulation
of eicosanoids are standard characteristics of TB-DM co-morbidity. Our data also
demonstrate that modulation in the eicosanoid levels reflect disease severity and extent
in TB and TB-DM and are modulated by ATT.
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INTRODUCTION
Tuberculosis (TB) and diabetes mellitus (DM) are two of
the most common diseases worldwide and often occur in
the same geographical regions (Dooley and Chaisson, 2009).
The occurrence of this co-morbidity poses a major threat to
the global program for elimination of tuberculosis (Lonnroth
et al., 2015). While a variety of clinical and epidemiological
studies have been performed in this dual disease process, very
few immunological or translational insights are available. The
presence of a hyper-inflammatory milieu is highly characteristic
of TB-DM co-morbidity and provides an opportunity for host-
directed therapies to function as an adjunct measure to control
this threat (Prada-Medina et al., 2017).
Eicosanoids are arachidonic acid derived lipid mediators
that elicit a panel of pro- and anti-inflammatory responses
and include prostaglandins, lipoxins, leukotrienes, and resolvins
(Tobin et al., 2013). The enzyme 5-lipoxygenase is essential
for the generation of lipoxin and leukotriene mediators from
arachidonic acid, while the enzymes cyclooxygenase−1 and 2 are
required for the generation of prostaglandins (Das, 2017). These
lipid mediators have been shown to exert major influence on
the outcomes of experimental M. tuberculosis (M. tb) infection
(Mayer-Barber and Sher, 2015). Published studies have reported
that leukotriene B4 (LTB4) and prostaglandin E2 (PGE2)
play a host protective role by mediating bacterial clearance,
while lipoxin A4 (LXA4) and 15-epi-lipoxin A4 (15-epi-LXA4)
play a pathogenic role by hampering the host inflammatory
response in TB (Mayer-Barber et al., 2014). Moreover, pro-
and anti-inflammatory eicosanoid ratios are associated with the
modulation of the host response to M. tb infection (Bafica et al.,
2005; Tobin et al., 2012). Published studies have also reported
that eicosanoid ratios in plasma were significantly increased in
active TB patients compared to latent TB or healthy controls
(Mayer-Barber et al., 2014). However, the role in eicosanoids in
human TB and more specifically TB-DM co-morbidity has been
poorly explored.
In this study, we elucidated the systemic levels of eicosanoids
at baseline and at the end of anti-tuberculosis treatment (ATT).
Our data reveal that DM differentially modulates the eicosanoid
levels in individuals with TB before and after completion of
treatment. Our data also show that certain eicosanoid levels
reflect baseline disease severity and extent in TB and TB-DM and
are modulated by ATT.
MATERIALS AND METHODS
Ethics Statement
The Ethics Committees of the Prof. M. Viswanathan Diabetes
Research Center and National Institute for Research in
Tuberculosis provided approval for this study. Informed written
consent was obtained from all individuals recruited for the study.
Study Population
Plasma samples were collected from 44 participants with
active pulmonary TB with diabetes mellitus (TB-DM) and 44
participants with active pulmonary TB (TB), 44 participants with
diabetes mellitus (DM), 30 healthy control participants with no
TB or diabetes (HC) recruited in Chennai, India. Pulmonary
TB was diagnosed based on smear and culture positivity for
M. tb. Chest X-rays were used to define cavitary disease (n =
23) and non-cavitary disease (n = 65) as well as unilateral (n
= 49) vs. bilateral (n = 39) lung involvement. Smear grades
were used to estimate bacterial burdens and classified as 1+ (n
= 33), 2+ (n = 33) and 3+ (n = 22). All participants with
active TB had no record of prior TB disease or ATT at the
time of enrolment. Oral glucose tolerance test and/or glycated
hemoglobin (HbA1c) levels (for known diabetics) was used to
diagnose glycemic status (DM or normoglycemia), according to
the WHO criteria. All the enrolled DM and HC participants
were Quantiferon TB gold assay negative, asymptomatic and with
normal chest X-rays. Standard ATT was administered to TB-DM
and TB participants using the directly observed treatment, short
course (DOTS) strategy. Fresh plasma samples were obtained
again from TB-DM and TB participants at the end of ATT (6
months). All TB-DM and TB participants were culture negative
forM. tb at this time point.
ELISA
Plasma levels of LXA4, 15-epi-LXA4, PGE2, and LTB4
were measured using the MyBioSource.com quantitative
measurement kit and plasma levels of IL-1α, IL-1β, IFNγ, and
TNFα were measured using Bio-Plex multiplex cytokine assay
system (Bio-Rad, Hercules, CA). The lowest detection limits
were as follows LXA4, 0.156 ng/mL; 15-epi-LXA4, 0.312 ng/mL;
PGE2, 7.8 pg/mL; LTB4, 15.6 pg/mL; IL-1α, 5.23 pg/mL; IL-1β,
3.96 pg/mL; IFNγ, 4.39 pg/mL, and TNFα, 3.24 pg/mL.
Statistical Analysis
Geometric means (GM) were used for measurements of central
tendency. Statistically significant differences between the four
groups were analyzed using the Kruskal-Wallis test with Dunn’s
correction for multiple comparisons. The Mann-Whitney test
was used to compare eicosanoid concentrations in TB individuals
with unilateral or bilateral lung lesions and cavitary or non-
cavitary disease. Linear trend post-test was used to compare
eicosanoid concentrations with smear grades (reflecting bacterial
burdens) and Spearman rank correlation was used to compare
eicosanoid concentrations with HbA1c levels. Analyses were
performed using GraphPad PRISM Version 8.
RESULTS
Study Population Characteristics
Table 1 depicts the demographic and biochemical features of the
study population. As shown, the TB-DM and TB groups did
not differ significantly in age, sex, smear, or culture grades at
baseline (Table 1).
Plasma Levels of Eicosanoids and Ratios
in TB and TB-DM
To determine the impact of TB and DM on eicosanoid
expression, wemeasured the plasma levels of LXA4, 15-epiLXA4,
PGE2, and LTB4 in TB-DM, TB, DM, and HC participants
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TABLE 1 | Demographic and clinical variables of the study groups and biochemical parameters in TB-DM, TB, DM, and HC.
Study demographics TB-DM TB DM HC
No. of subjects recruited 44 44 44 30
Gender (male/female) 34/10 27/17 30/14 15/15
Median age (range) 47 (25–70) 39 (24–67) 44 (33–68) 34 (23–55)
Smear grade: 0/1+/2+/3+ 0/14/19/11 0/19/18/7 NA NA
Cavitary disease (Y/N) 13/31 10/34 NA NA
Lung lesions (unilateral/bilateral) 24/20 25/19 NA NA
Fasting blood glucose, mg/dL 154 (111–417) 93 (73–103) 140 (95–311) 75 (70–109)
Glycated hemoglobin level, % 10.3 (7.3–15.6) 5.6 (5.0–5.8) 10 (6.9–12.5) 5.5 (5.0–5.9)
The values represent the geometric mean (and the 95% confidence intervals) except for age where the median (and the range) are depicted.
(Figure 1A). The levels of LXA4 (Geometric Mean (GM)
11.3 ng/ml in TB-DM vs. 6.6 ng/ml in TB, 1.3 pg/ml in DM
and 2.04 pg/ml in HC), 15-epiLXA4 (GM 6.8 ng/ml in TB-
DM vs. 3.9 ng/ml in TB, 1.4 ng/ml in DM and 1.7 ng/ml in
HC), and PGE2 (GM 10 pg/ml in TB-DM vs. 5.9 pg/ml in
TB, 2.5 pg/ml in DM and 2.4 pg/ml in HC) were significantly
elevated in TB-DM and DM group in comparison with TB
and HC group. In contrast, the levels of LTB4 (GM 170.3
pg/ml in TB-DM vs. 220.3 pg/ml in TB, 357.8 pg/ml in DM
and 329.8 pg/ml in HC) was significantly decreased in TB-DM
and DM group in comparison with TB and HC individuals.
Thus, TB-DM and TB were associated with significantly altered
plasma levels of eicosanoids. Next, to examine the association
of eicosanoid ratios with TB-DM and TB, we measured the
ratios of LXA4:LTB4, 15-epi-LXA4:LTB4, LXA4:PGE2, 15-epi-
LXA4:PGE2, and PGE2:LTB4 in TB-DM and TB individuals
(Figure 1B). The ratios of LXA4:LTB4 (GM 0.06643 in TB-DM
vs. 0.02994 in TB), 15-epi-LXA4:LTB4 (GM 0.03992 in TB-DM
vs. 0.01744 in TB), and PGE2:LTB4 (GM 0.05873 in TB-DM vs.
0.02691 in TB) were significantly increased in TB-DM compared
to TB. Thus, balance between lipid mediators is associated with
differences in TB and TB-DM.
LXA4 and 15-epiLXA4 Are Markers of
Disease Severity in TB and TB-DM
To determine the relationship among the plasma levels of
eicosanoids and disease severity in TB and TB-DM, we compared
plasma levels of LXA4, 15-epiLXA4, PGE2, and LTB4 in all
TB study participants with unilateral vs. bilateral disease and
cavitary vs. non-cavitary disease based on chest X-ray. As shown
in Figure 2A, the plasma levels of LXA4 (GM 14 ng/ml in
cavitary vs. 9 ng/ml in non-cavitary disease) and 15-epiLXA4
(GM 8.2 ng/ml in cavitary vs. 4.4 ng/ml in non-cavitary) were
significantly elevated in TB-DM and TB participants with
cavitary disease compared to those without. Similarly, as shown
in Figure 2B, the plasma levels of LXA4 (GM 12 ng/ml in
bilateral vs. 9 ng/ml in unilateral disease) were significantly
elevated in TB-DM participants with bilateral disease compared
to those with unilateral disease. To elucidate the relationship
between the ratios of eicosanoids and disease severity in TB and
TB-DM, we compared ratios of LXA4:LTB4, 15-epi-LXA4:LTB4,
LXA4:PGE2, 15-epi-LXA4:PGE2, and PGE2:LTB4 in all TB study
participants with unilateral vs. bilateral disease and cavitary
vs. non-cavitary disease based on chest X-ray. As shown in
Figure 2C, the ratios of LXA4:LTB4 (GM 0.06902 in cavitary vs.
0.0303550 in non-cavitary disease) and 15-epi-LXA4:LTB4 (GM
0.04095 in cavitary vs. 0.02299 in non-cavitary) were significantly
elevated in TB-DM and TB participants with cavitary disease
compared to those without. Similarly, as shown in Figure 2D,
the ratios of LXA4:LTB4 (GM 0.05959 in bilateral vs. 0.03628
in unilateral disease) and 15-epi-LXA4:LTB4 (GM 0.03531 in
bilateral vs. 0.02140 in unilateral disease) were significantly
elevated in TB-DM and TB participants with bilateral disease
compared to those with unilateral disease. Thus, disease severity
assessed radiographically in TB-DM and TB was associated with
elevated plasma levels of certain eicosanoids, most notably LXA4
and altered ratios of LXA4 or epi-LXA4 to LTB4.
LXA4 and 15-epiLXA4 Are Markers of
Bacterial Burden in TB and TB-DM
To determine the association of the plasma levels of eicosanoids
and bacterial burdens, we studied a correlation of the plasma
levels of LXA4, 15-epiLXA4, PGE2, and LTB4 in TB-DM and
TB study participants with smear grades from 1+ to 3+. As
shown in Figure 3A, LXA4 and 15-epiLXA4 showed a significant
positive correlation with smear grades in TB-DM and TB
participants, indicating a positive relationship of these factors
with bacterial burdens. To elucidate the relationship of the ratios
of eicosanoids and bacterial burdens, we studied the correlation
of the ratios of LXA4:LTB4, 15-epi-LXA4:LTB4, LXA4:PGE2, 15-
epi-LXA4:PGE2, and PGE2:LTB4 in TB-DM and TB participants
with smear grades. As shown in Figure 3B, LXA4:LTB4 and 15-
epi-LXA4:LTB4 showed a significant positive relationship with
smear grades in TB-DM and TB participants, demonstrating
a positive association of these factors with bacterial burdens.
Thus, disease severity by estimated bacterial burden in TB-DM
and TB was associated with increased systemic levels of certain
eicosanoids, most notably LXA4 and altered ratios of LXA4 or
epi-LXA4 to LTB4.
Decreased Plasma Levels of Eicosanoids
in TB-DM Following ATT
To determine whether the eicosanoid levels were altered by
ATT, we examined the plasma levels of eicosanoids in TB-DM
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FIGURE 1 | Altered plasma levels of eicosanoids in TB-DM and TB individuals. (A) The plasma levels of LXA4, 15-epi-LXA4, PGE2, and LTB4 were measured in
TB-DM (n = 44), TB (n = 44), DM (n = 44), and HC (n = 44) individuals at baseline. (B) Ratios of LXA4:LTB4, 15-epi-LXA4:LTB4, LXA4:PGE2, 15-epi-LXA4:PGE2,
and PGE2:LTB4 in TB-DM and TB individuals at baseline. The data are represented as scatter plots with each circle representing a single individual. (A) P-values were
calculated using the Kruskal-Wallis test with Dunn’s post-hoc for multiple comparisons. (B) P-values were calculated using Mann-Whitney test.
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FIGURE 2 | Elevated plasma levels of eicosanoids in cavitary and bilateral disease and relationship to bacterial burden in TB-DM and TB individuals. (A) The plasma
levels of LXA4, 15-epi-LXA4, PGE2, and LTB4 were measured in TB-DM and TB individuals with cavitary vs. non-cavitary disease. (B) The plasma levels of LXA4,
15-epi-LXA4, PGE2, and LTB4 were measured in TB-DM and TB individuals with bilateral vs. unilateral disease. (C) The ratios of LXA4:LTB4, 15-epi-LXA4:LTB4,
LXA4:PGE2, 15-epi-LXA4:PGE2, and PGE2:LTB4 were measured in TB-DM and TB individuals with cavitary vs. non-cavitary disease (D) The ratios of LXA4:LTB4,
15-epi-LXA4:LTB4, LXA4:PGE2, 15-epi-LXA4:PGE2, and PGE2:LTB4 were measured in TB-DM and TB individuals with bilateral vs. unilateral disease. The data are
represented as scatter plots with each circle representing a single individual. P-values were calculated using the Mann-Whitney test with Holm’s correction for
multiple comparisons.
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FIGURE 3 | Eicosanoid are markers of bacterial burden in TB and TB-DM. (A) The relationship between the plasma levels of LXA4, 15-epi-LXA4, PGE2, and LTB4 and
smear grades as estimated by sputum smears was examined in TB-DM and TB individuals. (B) The relationship between the ratios of LXA4:LTB4, 15-epi-LXA4:LTB4,
LXA4:PGE2, 15-epi-LXA4:PGE2, and PGE2:LTB4 and smear grades as estimated by sputum smears was examined in TB-DM and TB individuals. The data are
represented as scatter plots with each circle representing a single individual. For bacterial burden correlation P-values were calculated using the Linear trend post-test.
at baseline (pre-T) and at the completion of ATT (post-T). As
shown in Figure 4A, ATT resulted in significantly decreased
levels of LXA4 (GM of 11.31 ng/ml at pre-T vs. 6.1 ng/ml at post-
T), 15-epiLXA4 (GM of 6.7 ng/ml at pre-T vs. 1.2 ng/ml at post-
T) and PGE2 (GM of 10 pg/ml at pre-T vs. 6.3 pg/ml at post-T)
in TB-DM individuals. To elucidate whether the eicosanoid ratios
were also modulated by ATT, we examined the eicosanoid ratios
in TB-DM and TB at baseline (pre-T) and at the completion
of ATT (post-T). As shown in Figure 4B, ATT resulted in
significantly decreased ratios of LXA4:LTB4 (GM of 0.06643 at
pre-T vs. 0.03306 at post-T), 15-epi-LXA4:LTB4 (GM of 0.03992
at pre-T vs. 0.004554 at post-T), 15-epi-LXA4:PGE2 (GM of
0.6798 at pre-T vs. 0.1326 at post-T), and PGE2:LTB4 (GM of
0.05873 at pre-T vs. 0.03434 at post-T) in TB-DM individuals.
Thus, eicosanoid levels and eicosanoid ratios are significantly
altered in TB-DM by ATT.
Decreased Plasma Levels of Eicosanoids
in TB Following ATT
To examine whether the eicosanoid levels were modulated by
ATT, we studied the eicosanoid ratios in TB at baseline (pre-T)
and at the completion of ATT (post-T). As shown in Figure 5A,
ATT resulted in significantly decreased levels of LXA4 (GM of
6.5 ng/ml at pre-T vs. 3.1 ng/ml at post-T), 15-epiLXA4 (GM of
3.8 ng/ml at pre-T vs. 0.77 ng/ml at post-T), and PGE2 (GMof 5.9
pg/ml at pre-T vs. 3.5 pg/ml at post-T) and significantly increased
levels of LTB4 (GM of 220.3 pg/ml at pre-T vs. 283.8 pg/ml at
post-T) in TB individuals. Similarly, as shown in Figure 5B, ATT
resulted in significantly decreased levels of LXA4:LTB4 (GM of
0.02994 at pre-T vs. 0.01124 at post-T), 15-epi-LXA4:LTB4 (GM
of 0.01744 at pre-T vs. 0.002713 at post-T), 15-epi-LXA4:PGE2
(GM of 0.6479 at pre-T vs. 0.1883 at post-T), and PGE2:LTB4
(GM of 0.02691 at pre-T vs. 0.01441 at post-T) in TB individuals.
Thus, eicosanoid levels and eicosanoid ratios are significantly
altered in TB by ATT.
Circulating Eicosanoids Exhibit
Relationship With Pro-Inflammatory
Cytokines
We have previously measured the circulating levels of pro-
inflammatory cytokines (IL-1α, IL-1β, IFNγ, and TNFα) in
these individuals and shown that IL-1β, IFNγ, and TNFα
were significantly increased in TB patients with DM compared
to TB individuals (Kumar et al., 2013; Prada-Medina et al.,
2017). Since, LXA4, LTB4, and PGE2 have been described to
be associated with pro-inflammatory cytokine modulation in
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FIGURE 4 | Altered plasma levels of eicosanoids at the end of standard anti-tuberculosis therapy in TB-DM individuals. (A) The plasma levels of LXA4, 15-epi-LXA4,
PGE2, and LTB4 were measured in TB-DM individuals at baseline (pre-T) and at 6 months of ATT (post-T). (B) The ratios of LXA4:LTB4, 15-epi-LXA4:LTB4,
LXA4:PGE2, 15-epi-LXA4:PGE2, and PGE2:LTB4 were measured in TB-DM individuals at baseline (pre-T) and at 6 months of ATT (post-T). The data are presented as
line graphs with each line representing a single individual. P-values were calculated using the Wilcoxon signed rank test.
TB, we examined the association between the plasma levels
of eicosanoids in all TB individuals with pro-inflammatory
cytokines (Figure 6). As shown, the circulating levels of LXA4
showed a significant positive correlation, with IFNγ, TNFα IL-
1β and negative correlation with IL-1α levels. In addition, LTB4
exhibited a significant negative relationship with IFNγ and IL-1β
in all TB participants with and without DM at baseline, indicating
a significant involvement of these factors with cytokines.
DISCUSSION
Eicosanoids and prostaglandins are major lipid moieties of
considerable interest in metabolic biology. However, it is being
gradually accepted that these lipid molecules have the capability
to shape the immune response to infectious pathogens. Lipid
mediators of the eicosanoid family have been proven to have
influence on the outcome of the M. tb infection (Mayer-
Barber and Sher, 2015). Previously published studies have
also reveal that M. tb can also alter the host eicosanoid
metabolism as a survival strategy (Divangahi et al., 2010). The
interplay among the eicosanoids, PGE2 and LXA4 is known
to affect the type of cell death in infected macrophages. LXA4
enhances macrophage necrosis, resulting in cell death and
escape of M. tb to the extracellular milieu. PGE2 stimulates
macrophage apoptosis, resulting in membrane integrity, bacillary
containment and heightened immunity (Chen et al., 2008). LTB4,
via the regulation of TNFα production (Tobin et al., 2012), can
enhance attraction of neutrophils (Lammermann et al., 2013) and
lead to macrophage necrosis (Tobin et al., 2012). Our findings
clearly demonstrate the presence of elevated levels of LXA4,
15-epiLXA4, and PGE2 in TB-DM and TB at baseline, with
only LTB4 being present at lower levels compared to controls.
Our data also demonstrate a positive relationship between LXA4
and pro-inflammatory cytokines and a negative relationship
between LTB4 and pro-inflammatory cytokines, suggesting a
cross-regulation of eicosanoids with cytokine levels in TB.
Published findings report that high LXA4 favors the
mycobacterial infection (Amaral et al., 2013). Specifically, LXA4
can induce necrotic cell death of the infected macrophages
(Bafica et al., 2005). We have previously reported that LXA4
and 15-epi-LXA4 are significantly increased in the active TB
group compered to latent and healthy controls (Mayer-Barber
et al., 2014). In agreement with this report, our present finding
also confirms the presence of elevated levels of LXA4 and
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FIGURE 5 | Increased eicosanoids ratios at the end of standard anti-tuberculosis therapy in TB-DM and TB individuals. (A) The plasma levels of LXA4, 15-epi-LXA4,
PGE2, and LTB4 were measured in TB individuals at baseline (pre-T) and at 6 months of ATT (post-T). (B) The ratios of LXA4:LTB4, 15-epi-LXA4:LTB4, LXA4:PGE2,
15-epi-LXA4:PGE2, and PGE2:LTB4 were measured in TB individuals at baseline (pre-T) and at 6 months of ATT (post-T). The data are presented as line graphs with
each line representing a single individual. P-values were calculated using the Wilcoxon signed rank test.
15-epi-LXA4 in TB individuals who are with and without
diabetes compared to DM and HC. More interestingly, our
data also highlight an important involvement of LXA4 and 15-
epi-LXA4 with both the amount of pathology in TB as well
as the degree of disease. Finally, our data disclose a direct
correlation of LXA4 and 15-epi-LXA4 levels with bacterial
burdens, perhaps suggesting that high LXA4 and 15-epi-
LXA4 reflect an inflammatory environment favorable for M.
tb replication. This is further corroborated by the fact that
LXA4 and 15-epi-LXA4 levels are significantly reduced following
successful chemotherapy. Interestingly, our data also reveal that
only LXA4 and not 15-epiLXA exhibits a significant positive
relationship with pro-inflammatory cytokines—IL-1β, IFNγ, and
TNFα. Thus, LXA4 in TB-DM and TB is a major biomarker of
disease severity and bacterial burden.
Earlier studies have reported that excess LTB4 production
leads to increased TNF dependent macrophage cell death, while
diminished levels LTB4 leads to a relative increase in LXA4,
which in turn results in cell death due to loss of bacterial
control (Tobin et al., 2012). Our current finding also reveals the
presence of diminished levels of LTB4 in TB individuals who are
with and without diabetes compared to DM and HC. Moreover,
our findings reveal certain important features of eicosanoid
imbalance and its association with TB-DM and DM. Thus, the
ratios of LXA4: LTB4 and 15epiLXA4: LTB4 are significantly
increased in TB-DM compared to TB alone. Our data also reveal
that the ratio of LXA4 to LTB4 levels and of 15-epiLXA4 to LTB4
levels appear to be associated with both disease severity/extent as
well as bacterial burdens in TB-DM and TB. Hence, eicosanoid
balance between the lipoxins and LTB4 seems to be associative
factors with lung pathology and bacterial burden in TB-DM and
TB. This is further corroborated by the decrease in the ratios
following ATT in both TB-DM and TB. Finally, LTB4 levels in
TB-DMandTB individuals is negatively associated with the levels
of the pro-inflammatory cytokines—IL-1α and IL-1β.
Animal model studies have reported PGE2 confers resistance
against M. tb infection, while LXA4 promotes bacterial growth
(Bafica et al., 2005; Chen et al., 2008; Divangahi et al., 2009).
Thus, during M. tb infection, the balance of PGE2 and LXA4
is important in regulating the relative amounts of apoptosis
and necrosis, which is an important feature in the control
of intracellular infection. Moreover, studies using the genetic
analysis of the susceptibility of zebrafish to M. marinum have
validated the important role of these host lipid pathways in
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FIGURE 6 | Significant correlation between plasma levels of eicosanoids and pro-inflammatory cytokines in all TB individuals. (A) The relationship between the plasma
levels of lipoxin A4 and cytokines was examined in all TB individuals with and without DM at baseline. (B) The relationship between the plasma levels of LTB4 and
cytokines was examined in all TB individuals with and without DM at baseline The data are represented as scatter plots with each circle representing a single
individual. P-values were calculated using the Spearman Rank Correlation.
innate immunity (Tobin et al., 2010). Our data clearly shows
that the presence of elevated levels of PGE2 are observed in
TB individuals who are with and without diabetes compared to
DM and HC, but our data do not reveal a direct correlation
of PGE2 with lung pathology or bacterial burdens. However,
we do observe significantly decrease levels of PGE2 following
ATT in both TB-DM and TB individuals, suggesting that PGE2
is an important factor in TB disease. Our data also reveal
no association of lipoxin to PGE2 or PGE2 to LTB4 ratios
in the pathology of TB-DM and TB. Thus, PGE2 appears to
play a less important associative role with disease pathology or
bacterial burden in TB-DM and TB. Moreover, our data did
not reveal any significant association between PGE2 levels and
pro-inflammatory cytokines in TB or TB-DM.
There is an increasing appreciation of the distinct roles that
lipid mediators play in regulating inflammatory responses during
M. tb infection (Tobin and Ramakrishnan, 2013). To define the
outcome and severity of mycobacterial infection, the balance
between the lipid mediators are important (Pedruzzi et al.,
2016). In this study, we report that ratios of LXA4:LTB4, 15-
epi-LXA4:LTB4, and PGE2:LTB4 were significantly enhanced
in TB-DM and correlated with disease severity and in-turn
diminished following ATT. The limitations of our study are the
limited sample size, the estimation of eicosanoid levels only in
the plasma and the absence of mechanistic insights. Despite
this, our study contributes to the growing body of literature
on the regulation of innate immune responses in TB-DM
co-morbidity. To our knowledge, no studies have reported
correlation of LXA4:LTB4 and 15-epi-LXA4:LTB4 with disease
severity in TB-DM comorbidity. Our data clearly reveals that
changes in eicosanoids might reflect a perfectly balanced host
response needed to control imbalance in TB diabetes comorbidity
linked with outcome of M. tb infection. Finally, our data also
complements the growing understanding of pathophysiology in
TB diabetes comorbidity.
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